SCNI — Scinai Immunotherapeutics Ltd.
Is SCNI overbought or oversold? Here is the current MarketMoodz read.
Scinai Immunotherapeutics Ltd. (SCNI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.40. The rating moved from Strong Oversold to Oversold on November 10, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$0.40
- Last changeMoved from Strong Oversold to Oversold on November 10, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Scinai Immunotherapeutics Ltd. (SCNI) is a highly speculative, microcap healthcare equity with limited public filings and low liquidity. The broader market currently favors large-cap pharma and defensive healthcare exposures, which constrains capital flows to smaller issuers. Absent clear financial disclosure or near-term confirmed catalysts, upside is dependent on binary events (partnering, financing, or positive clinical/regulatory news) while downside is elevated due to dilution and liquidity risk. Short-term price action will likely be driven by retail momentum and any company-specific announcements; medium-term prospects hinge on funding clarity and tangible clinical or commercial progress.
Key factors
- Very limited public financial disclosure and no recent EDGAR filing context increases information asymmetry for Scinai Immunotherapeutics Ltd. (SCNI).
- Microcap equity with low absolute share price and likely low liquidity — amplifies volatility and execution risk for investors.
- Sector backdrop favors large-cap pharma and defensive healthcare flows, which can reduce capital and M&A interest in small biotech names.
- Convertible-debt and financing dynamics in the broader biotech/diagnostics space raise the probability of dilution or expensive capital for smaller issuers.
- Retail chatter showing optimism around upcoming releases creates occasional short-term momentum opportunities despite sparse fundamentals.
- Binary upside exists if the company secures a partner, positive clinical news, or a financing that improves runway.
Risks
- High dilution risk from equity or convertible financings to fund operations absent clear revenue streams.
- Binary clinical or regulatory outcomes (if applicable) could produce large down moves on negative news.
- Severely limited financial transparency and lack of recent filings increase the chance of undisclosed liabilities or cash constraints.
- Low liquidity leading to sharp price moves, wide bid/ask spreads, and difficulty entering/exiting positions.
- Sector rotation toward large-cap, defensive pharma could reduce investor appetite and secondary-market demand for SCNI.
- Competitive pressure from better-capitalized firms and potential inability to commercialize without partners.
See today's live rating, score and targets
Members see the live hourly rating for SCNI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.